creon magasýruþolið hart hylki 35.000
viatris aps - pancreatinum - magasýruþolið hart hylki - 35.000
creon (pankreon) magasýruþolið hart hylki 10.000
viatris aps - pancreatinum - magasýruþolið hart hylki - 10.000
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
zesuva (sunitinib alvogen) hart hylki 12,5 mg
zentiva k.s.* - sunitinibum inn - hart hylki - 12,5 mg
zesuva (sunitinib alvogen) hart hylki 25 mg
zentiva k.s.* - sunitinibum inn - hart hylki - 25 mg
zesuva (sunitinib alvogen) hart hylki 50 mg
zentiva k.s.* - sunitinibum inn - hart hylki - 50 mg
sandostatin stungulyf, lausn 100 míkróg/ml
novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 100 míkróg/ml
sandostatin stungulyf, lausn 50 míkróg/ml
novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 50 míkróg/ml
sandostatin lar stungulyfsstofn og leysir, dreifa 10 mg
novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 10 mg